Search

News Analysis of the Benefits of Combining Enalapril/Bisoprolol in Patients with Acute MI

A recently published retrospective analysis compared the outcomes achieved by administering enalapril alone and in combination with bisoprolol in patients after acute myocardial infarction over a period of 1 year.

Source: Cardiovascular Continuum 13. 5. 2024

News Ceftaroline vs. Vancomycin in the Treatment of Acute Pulmonary Exacerbation of Cystic Fibrosis

Up to 25% of patients with cystic fibrosis are colonized with methicillin-resistant Staphylococcus aureus (MRSA). The first-line drug for acute pulmonary exacerbation is vancomycin. The study presented below examined the efficacy and safety of an alternative treatment with ceftaroline (a 5th generation cephalosporin) for this indication.

Source: Anti-Infectives 22. 4. 2022

News Height as an Independent Risk Factor for Varicose Veins

Authors of a study published in the journal Circulation analyzing data from nearly half a million people found another risk factor for the development of varicose veins –⁠ a person's height. They further assessed the possible causal role in the development of this pathology.

Source: Venous Insufficiency 1. 3. 2021

News Proposal of a New Treatment Sequence Algorithm for Heart Failure with Reduced Ejection Fraction

John McMurray and Milton Packer published a proposal for a new treatment sequence algorithm for patients with heart failure with reduced ejection fraction (HFrEF) based on current findings in the 2021 issue of Circulation. This procedure consists of three steps and, according to the authors, should be initiated in patients who have achieved euvolemia through the use of diuretics.

Source: Heart Failure 21. 2. 2022

News Is it beneficial to combine etanercept and methotrexate in the treatment of psoriatic arthritis?

The study presented below by Canadian, American, and British authors focused on comparing the efficacy of monotherapy with methotrexate, etanercept, and their combination in patients with psoriatic arthritis.

Source: Arthritis 28. 3. 2022

News Does Sacubitril/Valsartan Prevent Myocardial Remodeling in Heart Failure Patients with Type 2 Diabetes?

The PROVE-HF study demonstrated reverse myocardial remodeling in patients with chronic heart failure with reduced ejection fraction. About 30–50% of heart failure patients have type 2 diabetes mellitus (DM2). The subject of a post hoc analysis of the PROVE-HF study was to find out whether this benefit of sacubitril/valsartan can be expected in patients with DM2 as well.

Source: Chronic Heart Failure and Lipidology 20. 5. 2021

News Bimekizumab in the Treatment of Psoriasis After Failure of (Not Only) Anti-IL-17A Antibodies –⁠ Case Reports

German authors last year described the first 2 cases of patients with psoriasis in whom treatment with, among other things, anti-IL-17A antibodies failed, but who responded to the blockade of interleukins IL-17A/IL-17F with bimekizumab after its approval by the European Medicines Agency (EMA).

Source: Psoriasis 2. 4. 2023

News Bilastine in the treatment of allergic rhinitis –⁠ meta-analysis shows advantage of lower somnolence

A newly published systematic review and meta-analysis evaluate the efficacy and safety of bilastine in the treatment of allergic rhinitis (AR), which includes symptoms of common rhinitis and allergic sensitization upon allergen exposure. The disease causes significant discomfort for patients and reduces their quality of life, which is why its control is essential for their daily functioning.

Source: Allergic Reactions 24. 5. 2022

News Prim. Pavel Jindra: Biosimilars are an accessible and effective treatment modality in hematooncology

“Based on our experience so far, biosimilars represent an effective and safe alternative to original molecules. We are not afraid to use them anywhere in approved indications, and we are not afraid of switching either. Biosimilars are a significant step towards greater accessibility of hematooncological treatment for a wide group of patients,” states the head of the Hematology-Oncology Department of FN Plzeň, MUDr. Pavel Jindra, Ph.D., in our current interview.

Source: Oncological Treatment 24. 3. 2022

News First Effective Pharmacotherapy Modality for Negative Symptoms in Schizophrenia

Negative symptoms of schizophrenia significantly limit the quality of life and overall functioning of the patient. However, there have been no suitable medications to effectively suppress these symptoms until now. This is expected to change with the introduction of cariprazine into the antipsychotic armamentarium, as suggested by promising results from an analysis published last year in the journal European Psychiatry.

Source: Schizophrenia and Antipsychotics 21. 2. 2020

News Cell-Based Implant as a Stable System for Biological Therapy Delivery

A team of scientists from Washington University in St. Louis focused on the possibility of delivering biological inhibitors for the treatment of rheumatoid arthritis using modified induced pluripotent stem cells. To verify the effectiveness of the therapy, they used a mouse model of rheumatoid arthritis, and their results represent progress in the development of rheumatoid arthritis treatment.

Source: Arthritis 19. 11. 2021

News Increased Sympathetic Activity in Patients with Masked Uncontrolled Hypertension

Not all hypertensive patients who have normal blood pressure readings in the doctor's office actually have controlled hypertension. Recent studies suggest that so-called masked uncontrolled hypertension may be linked to increased sympathetic activity.

Source: Cardiovascular Continuum 25. 1. 2021

News Impact of Body Mass Index on Survival and Treatment Outcomes of Metastatic Colorectal Cancer

A pooled analysis of 25 studies with patients in the first line of treatment for metastatic colorectal cancer (mCRC) evaluated the prognostic and predictive significance of body mass index (BMI). Until its publication in 2015, only the adverse impact of low and high BMI on outcomes in patients with early stages of colorectal cancer was known.

Source: Colorectal Cancer 17. 5. 2020

News Position of aPCC in the Treatment of Hemophilia A Complicated by the Development of Inhibitors

Activated prothrombin complex concentrates (aPCC) are essential drugs that not only allow the control of bleeding in patients with congenital hemophilia A and inhibitors but also help to prevent such bleeding. A recent review article by experts from several European institutions provides an up-to-date view of the development, challenges, and future directions in the use of aPCC in the treatment of hemophilia.

Source: Hemophilia 2. 11. 2020

News Administration of RAAS Inhibitors in Czech Patients with Heart Failure in Real Practice

A partial analysis of data from the national register of reimbursed health care focused on the epidemiology of heart failure in the Czech Republic showed how inhibitors of the renin-angiotensin-aldosterone system (RAAS), i.e., angiotensin-converting enzyme inhibitors (ACEi), AT1 receptor blockers for angiotensin II (ARBs, sartans), and angiotensin receptor and neprilysin inhibitors (ARNI), were used in real practice in the years 2012–2018 in patients with this disease.

Source: Sartans in the Treatment of Hypertension 24. 10. 2022